| Blocking CGRP in migraine patients–a review of pros and cons M Deen, E Correnti, K Kamm, T Kelderman, L Papetti, E Rubio-Beltrán, ... The journal of headache and pain 18, 1-9, 2017 | 340 | 2017 |
| Gender aspects of CGRP in migraine A Labastida-Ramírez, E Rubio-Beltrán, CM Villalón, ... Cephalalgia 39 (3), 435-444, 2019 | 144 | 2019 |
| Long COVID headache C Tana, E Bentivegna, SJ Cho, AM Harriott, D García-Azorín, ... The journal of headache and pain 23 (1), 93, 2022 | 137 | 2022 |
| Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? E Rubio-Beltrán, A Labastida-Ramírez, CM Villalón, ... Pharmacology & therapeutics 186, 88-97, 2018 | 119 | 2018 |
| Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system A Labastida-Ramírez, E Rubio-Beltrán, KA Haanes, KY Chan, IM Garrelds, ... Pain 161 (5), 1092-1099, 2020 | 103* | 2020 |
| Characterization of binding, functional activity, and contractile responses of the selective 5‐HT1F receptor agonist lasmiditan E Rubio‐Beltrán, A Labastida‐Ramírez, KA Haanes, A van den Bogaerdt, ... British Journal of Pharmacology 176 (24), 4681-4695, 2019 | 93* | 2019 |
| PACAP38 and PAC1 receptor blockade: a new target for headache? E Rubio-Beltrán, E Correnti, M Deen, K Kamm, T Kelderman, L Papetti, ... The journal of headache and pain 19, 1-11, 2018 | 92 | 2018 |
| Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries E Rubio-Beltran, KY Chan, AHJ Danser, A MaassenVanDenBrink, ... Cephalalgia 40 (4), 357-366, 2020 | 66 | 2020 |
| Protective effects of PACAP in ischemia D Reglodi, A Vaczy, E Rubio-Beltran, A MaassenVanDenBrink The Journal of Headache and Pain 19, 1-9, 2018 | 63 | 2018 |
| Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine JL Bussiere, R Davies, C Dean, C Xu, KH Kim, HM Vargas, GJ Chellman, ... Regulatory Toxicology and Pharmacology 106, 224-238, 2019 | 62* | 2019 |
| Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries E Rubio-Beltrán, A Labastida-Ramírez, KA Haanes, A van den Bogaerdt, ... Cephalalgia 39 (14), 1735-1744, 2019 | 34 | 2019 |
| Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models KA Haanes, A Labastida-Ramírez, FW Blixt, E Rubio-Beltrán, CM Dirven, ... Cephalalgia 39 (11), 1421-1434, 2019 | 32 | 2019 |
| Local endothelial DNA repair deficiency causes aging-resembling endothelial-specific dysfunction PK Bautista-Niño, E Portilla-Fernandez, E Rubio-Beltrán, ... Clinical Science 134 (7), 727-746, 2020 | 31 | 2020 |
| Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: implications for the efficacy and safety of novel antimigraine medications S de Vries Lentsch, E Rubio-Beltrán, A MaassenVanDenBrink Maturitas, 2020 | 29 | 2020 |
| Hypothalamic paraventricular nucleus stimulation enhances c-Fos expression in spinal and supraspinal structures related to pain modulation M Condés-Lara, G Martínez-Lorenzana, E Rubio-Beltrán, ... Neuroscience research 98, 59-63, 2015 | 28 | 2015 |
| Is CGRP Receptor Blockade Cardiovascularly Safe? Appropriate Studies Are Needed. E Rubio-Beltrán, D Duncker, CM Villalón Headache 58 (8), 1257-1258, 2018 | 24 | 2018 |
| Understanding CGRP and cardiovascular risk E Rubio-Beltrán, AM van den Brink Calcitonin gene-related peptide (CGRP) mechanisms: focus on migraine, 131-140, 2019 | 21 | 2019 |
| Health equity, care access and quality in headache–part 2 B Raffaelli, E Rubio-Beltrán, SJ Cho, R De Icco, A Labastida-Ramirez, ... The journal of headache and pain 24 (1), 167, 2023 | 20 | 2023 |
| Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease DM Bovée, E Uijl, D Severs, E Rubio-Beltrán, R van Veghel, ... American Journal of Physiology-Renal Physiology 320 (4), F654-F668, 2021 | 14 | 2021 |
| Selective phosphodiesterase 1 inhibition ameliorates vascular function, reduces inflammatory response, and lowers blood pressure in aging animals K Golshiri, EA Ataabadi, E Rubio-Beltran, S Dutheil, W Yao, GL Snyder, ... The Journal of pharmacology and experimental therapeutics 378 (2), 173-183, 2021 | 12 | 2021 |
Alejandro Labastida-RamírezThe University of Manchester, Division of Neuroscience, Faculty of Biology, Medicine & HealthDirección de correo verificada de manchester.ac.uk